Overview 2018-11-08T20:39:54+00:00

We Develop, Manufacture & Commercialize
Clinically Important, Technically Challenging mAbs

As a a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex mAb therapeutics, Oncobiologics leverages our BioSymphony™ Platform to produce high-quality innovative and biosimilar mAb candidates in an efficient and cost-effective manner.

Our Strategy

Our goal is to utilize the BioSymphony Platform to identify, develop, manufacture and commercialize technically challenging and commercially attractive mAb biosimilars on an accelerated timeline in a cost-effective manner.

To achieve this goal, we leverage the BioSymphony Platform and its capabilities to provide funding for our biosimilar development program while we continue to develop our pipeline.

  • Expanding our pipeline to include innovative mAb candidates.

  • Rapidly advancing our lead biosimilar product candidates through late-stage clinical development in emerging markets.

  • Advancing our pre-clinical biosimilar pipeline towards clinical development.

  • Seeking opportunities to maximize the value of our pre-clinical and clinical pipeline via co-development partnerships and/or licensing the development and commercialization rights where appropriate.


Our BioSymphony platform was designed to achieve speed and pricing flexibility for our portfolio products.


Through skill and experience, our team expertly handles the challenges of mAb development